WADA deny giving Chris Froome a legal loophole by avoiding pharmacokinetic study

Chris Froome (Team Sky)

The World Anti-Doping Agency (WADA) has told Cyclingnews that Chris Froome has been treated like any other athlete, with WADA carefully adhering to its own rules in a unique case, despite Froome not undergoing a controlled pharmacokinetic study (CPKS) to try to replicate his high level of salbutamol. WADA's science director Dr Oliver Rabin insisted that Froome's verdict does not undermine the fight against specific substances such as salbutamol. However, he admitted that there should perhaps be a review of the medical guidelines on the amount of salbutamol that is legally allowed as asthma medication, to help reduce any possible grey areas of abuse. Froome's urine sample from stage 18 of the Vuelta a España was over WADA's threshold limit for the controlled drug used to treat asthma. Under new rules introduced during the winter, the amount of salbutamol in Froome's sample was corrected for specific gravity to counter the ...

Read on Cycling News


More Like This

Card image cap

WADA will not appeal UCI verdict on Chris Froome salbutamol case

View
Card image cap

UCI says no reasoned decision will be released for Froome case, elaborates on related topics

View
Card image cap

Opinion: Why WADA and the UCI’s handling of the Froome case is damaging to sport

View
Card image cap

Analysis: WADA appears to contradict UCI over Froome case decision

View
Card image cap

UK Anti-Doping data a blow to Chris Froome's salbutamol defence

View
Card image cap

UCI drops investigation into Froome, says it accepts no rules were broken in Salbutamol case

View
Card image cap

Petacchi feels vindicated by resolution of Chris Froome case

View
Card image cap

WADA decides against Froome anti-doping appeal

View
Card image cap

WADA explains why it cleared Froome, Prudhomme confirms rider can compete in Tour

View
Card image cap

What the newest salbutamol study means for Froome

View